Vice Chairman And Ceo

We were all worried about the Brexit vote this week, but I think now we are going to grapple with 'Rexit'. I think Rajan going out, of course, will not be taken well by the market. The initial reaction will obviously be down for the market, said Ramesh Damani, Member, BSE.

Digital biz share in revenue may hit 30% over 2 quarters: Zensar

We are particularly excited about digital e-commerce and going forward that is going to be spectacular for Zensar, says Ganesh Natarajan, Vice Chairman and CEO of Zensar Technologies

HDFC Q1FY14 net profit seen up 20%

The housing finance company is expected to expand its loans by 19-20 percent year-on-year (y-o-y) during the three-month period. The lender may see an incremental increase of 4-5 percent quarter-on-quarter.

May raise USD 500 million via ECB: HDFC‘s Keki Mistry

Keki Mistry said HDFC will target individual loan growth of 18-20 percent over a sustained period of time on an annually compounded basis. It might however, be a little higher or lower in certain years. Additional tax benefits on home loans will also push housing growth in FY14, says vice-chairman and CEO – Keki Mistry.

Don't see any stress in retail loans in coming qtrs: HDFC

Mortgage lender HDFC on Tuesday met the market expectation in its first quarter results. However, a section of market participants are a bit apprehensive of the quality of retail assets. In an interview with moneycontrol.com the lender‘s vice-chairman and CEO - Keki Mistry sounded confident of its retail home loan portfolio.

Dr Reddy's gets USFDA ok for deep vein thrombosis injection

Dr Reddy’s Laboratories has received final approval from the US Food and Drugs Administration (FDA) to sell Fondaparinux Sodium injection, which is used for the treatment and prevention of deep vein thrombosis (DVT).